Triglyceride-glucose index as a potential biomarker in acute central serous chorioretinopathy
Öz
Purpose: The aim of this study is to compare triglyceride-glucose index (TGI) levels in patients with acute central serous chorioretinopathy (CSCR), chronic CSCR, and healthy controls, and to the value of TGI in indicating the risk of acute CSCR.
Materials and Methods: This retrospective study included 20 patients with acute CSCR, 20 patients with chronic CSCR, and 40 healthy controls. The TGI was calculated using fasting plasma triglyceride and glucose levels, and values were compared between groups. A receiver operating characteristic (ROC) curve was used to calculate the optimal TGI cut-off value, sensitivity, and specificity between the acute CSCR and control groups.
Results: There were no statistically significant differences between the groups in terms of age and sex. The TGI value was 8.48±0.29 in the control group, 8.91±0.34 in the acute CSCR group, and 8.59±0.40 in the chronic CSCR group (p<0.001 for control vs. acute CSCR; p=0.703 for control vs. chronic CSCR; p=0.011 for acute vs. chronic CSCR). The optimal ROC cut-off value of TGI between the control and acute CSCR groups was calculated as 8.74 with 75% sensitivity and 85% specificity (AUC: 0.835, p<0.001, 95% CI 0.719-0.951).
Conclusion: Caution should be exercised in patients with acute CSCR regarding the presence of underlying cardiovascular disease. Additionally, this biomarker, which can be easily measured through routine blood testing, may serve as a potentia
Anahtar Kelimeler
Central Serous Chorioretinopathy, Triglyceride, Glucose, Triglyceride-Glucose Index, Blood-Lipid Profile
Kaynakça
- Wang M, Munch IC, Hasler PW, Prünte C, Larsen M. Central serous chorioretinopathy. Acta Ophthalmol (Copenh). 2008;86:126 45.
- Gelber GS, Schatz H. Loss of vision due to central serous chorioretinopathy following psychological stress. Am J Psychiatry. 1987;144:46–50.
- Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology. 2008;115:169–73.
- Daruich A, Matet A, Behar-Cohen F. Central serous chorioretinopathy. Dev Ophthalmol. 2017;58:27–38.
- Sahoo NK, Govindhari V, Bedi R, Goud A, Singh R, Wu L et al. Subretinal hyperreflective material in central serous chorioretinopathy. Indian J Ophthalmol. 2020;68:126–29.
- Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N et al. Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res. 2015;48:82–118.
- Yannuzzi LA. Type A behavior and central serous chorioretinopathy. Trans Am Ophthalmol Soc. 1986;84:799–845.
- Haimovici R, Koh S, Gagnon DR, Lehrfeld T, Wellik S; Central Serous Chorioretinopathy Case-Control Study Group. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology. 2004;111:244–9.
- Chen SN, Chen YC, Lian I. Increased risk of coronary heart disease in male patients with central serous chorioretinopathy: Results of a population-based cohort study. Br. J. Ophthalmol. 2014;98:110–14.
- Tsai DC, Huang CC, Chen SJ, Chou P, Chung CM, Chan WL et al. Central serous chorioretinopathy and risk of ischaemic stroke: A population-based cohort study. Br. J. Ophthalmol. 2012;96:1484–88.
